Moneycontrol PRO
Loans
Sansaar
HomeNewsSunpharmaceuticalindustries

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Pharma Q3: New launches, generic drug demand to aid growth

    Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

  • Pharmaceutical results preview for Q3FY12: Emkay

    Pharmaceutical results preview for Q3FY12: Emkay

    Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

  • Limited competition, Forex gains pump Taro nos: Sun Pharma

    Limited competition, Forex gains pump Taro nos: Sun Pharma

    In an interview to CNBC-TV18, Uday Baldota of Sun Pharma says the results of Taro, have been boosted by lack of competition and Forex gains. With 'very strong numbers' reported by Taro this quarter, Badola says its delisting process is still ongoing.

  • Sun Pharma Q1 PAT seen down 13% to Rs 489 cr (YoY)

    Sun Pharma Q1 PAT seen down 13% to Rs 489 cr (YoY)

    Sun Pharma is to announce its first quarter results. According to CNBC-TV18's estimates, the company's Q1FY12 revenues are seen up 22% to Rs 1709 crore versus Rs 1400 crore, year-on-year, YoY.

  • Apr-June qtr: Pharma cos to see healthy sales, sick margins

    Apr-June qtr: Pharma cos to see healthy sales, sick margins

    Pharmaceutical sector has been in the pink of health this year with most stocks outperforming the broader market since the beginning of April. However, there could be some suffering ahead.

  • Sun Pharma Jun qtr PAT seen dn 19% at Rs 458 cr

    Sun Pharma Jun qtr PAT seen dn 19% at Rs 458 cr

    PINC Research has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Sun Pharma's June quarter net revenues are expected to go up by 21.6% at Rs 1702.1 crore, year-on-year, (YoY) basis.

  • Sun Pharma eyes revenue growth of 28-30% in FY12

    Sun Pharma eyes revenue growth of 28-30% in FY12

    Sun Pharmaceutical is eyeing revenue growth of 28-30% in FY12, said Uday Baldota of Sun Pharma. In an interview to CNBC-TV18, Baldota said that Taro Pharmaceutical Industries reported strong margins this quarter.

  • The good, the bad & the ugly of Q4 earnings

    The good, the bad & the ugly of Q4 earnings

    The score card is out and it’s been a mixed bag. Amidst inflationary worries and volatile global cues, many bigwigs disappointed this quarter while others came out with flying colours.

  • Sun Pharma Mar qtr PAT seen up at Rs 270.8 cr: MOST

    Sun Pharma Mar qtr PAT seen up at Rs 270.8 cr: MOST

    Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Sun Pharma March quarter sales are expected to go up by 29.1% at Rs 1432.1 crore, year-on-year, (YoY) basis.

  • Sun Pharma Q3 PAT seen up 32% to Rs 446 cr

    Sun Pharma Q3 PAT seen up 32% to Rs 446 cr

    Country's largest drugmaker by market value Sun Pharmaceutical is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax (PAT) is expected to go up by 32% to Rs 446 crore in Q3FY11 as against Rs 339 crore in Q3FY10.

  • Sun Pharma Dec qtr PAT seen up 32% at Rs 447.4cr: Angel

    Sun Pharma Dec qtr PAT seen up 32% at Rs 447.4cr: Angel

    Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Sun Pharma December quarter net sales are expected to go up by 48.2% to Rs 1,513 crore, Year-on-Year, (Y-o-Y) basis.

  • Sun Pharma Dec qtr PAT seen up 10.23% at Rs 373.7cr: Karvy

    Sun Pharma Dec qtr PAT seen up 10.23% at Rs 373.7cr: Karvy

    Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Sun Pharmaceutical Industries December quarter sales are expected to go up by 48.31% at Rs 1514.1 crore, Year-on-Year, (YoY) basis.

  • Sun Pharma Dec qtr PAT seen up 19.7% at Rs 394.2cr: Emkay

    Sun Pharma Dec qtr PAT seen up 19.7% at Rs 394.2cr: Emkay

    Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Sun Pharma December quarter sales are expected to go up by 55.3% to Rs 1585.9 crore, Year-on-Year, (Y-o-Y) basis.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347